R. G. Liao

发表

Facilitating a culture of responsible and effective sharing of cancer genome data

Rachel G Liao, D. Haussler, W. Sellers, 2016, Nature Medicine.

A federated ecosystem for sharing genomic, clinical data

Rachel G Liao, D. Haussler, A. Philippakis, 2016, Science.

Towards a global cancer knowledge network: dissecting the current international cancer genomic sequencing landscape

L. F. A. Wessels, D. J. Vis, Rachel G Liao, 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

Abstract 2: FGFR3 as a therapeutic target in squamous cell lung carcinoma

A. Sivachenko, G. Getz, M. Meyerson, 2012 .

A first update on mapping the human genetic architecture of COVID-19

Eurie L. Hong, E. F. Perez, Rachel G Liao, 2022, Nature.

Determining barriers to effective data sharing in cancer genomic sequencing initiatives: A Global Alliance for Genomics and Health (GA4GH) survey.

M. Caulfield, L. Esserman, M. Watson, 2016 .

Inhibitor-sensitive FGFR2 and FGFR3 mutations in lung squamous cell carcinoma.

Chandra Sekhar Pedamallu, Gad Getz, Kwok-Kin Wong, 2013, Cancer research.

BRCA Challenge: BRCA Exchange as a global resource for variants in BRCA1 and BRCA2

Gunnar Rätsch, Brian Craft, David Haussler, 2018, PLoS genetics.

Mapping the human genetic architecture of COVID-19

Mattia G. Bergomi, Christopher M. DeBoever, Matthew A. Wiles, 2021, Nature.

Functional Studies of Candidate Oncogenes in Non-Small Cell Lung Cancer

Rachel G Liao, R. G. Liao, 2013 .

RAS–MAPK Reactivation Facilitates Acquired Resistance in FGFR1-Amplified Lung Cancer and Underlies a Rationale for Upfront FGFR–MEK Blockade

Rachel G Liao, M. Meyerson, P. Hammerman, 2018, Molecular Cancer Therapeutics.

Inhibitor-Sensitive FGFR 2 and FGFR 3 Mutations in Lung Squamous Cell Carcinoma

Rachel G Liao, A. Sivachenko, G. Getz, 2013 .

Ligand associated ERBB2/3 activation confers acquired resistance to FGFR inhibition in FGFR3 dependent cancer cells

Rachel G Liao, P. Hammerman, Kwok-Kin Wong, 2014, Oncogene.

Kinase domain activation of FGFR2 yields high-grade lung adenocarcinoma sensitive to a Pan-FGFR inhibitor in a mouse model of NSCLC.

M. Meyerson, P. Hammerman, Kwok-Kin Wong, 2014, Cancer research.

Development of covalent inhibitors that can overcome resistance to first-generation FGFR kinase inhibitors

Rachel G Liao, S. Gaudet, P. Jänne, 2014, Proceedings of the National Academy of Sciences.

A Loss-of-Function Splice Acceptor Variant in IGF2 Is Protective for Type 2 Diabetes

Rachel G Liao, J. Lane, C. Hartl, 2017, Diabetes.

Abstract 5287: Heterogeneity of mutation calling and annotation: a survey of cancer next-generation sequencing initiatives by the Global Alliance for Genomics and Health (GA4GH):

Subha Madhavan, Emmanuel Dias-Neto, Thomas J. Hudson, 2016 .

Targeted therapy for squamous cell lung cancer.

Rachel G Liao, M. Meyerson, P. Hammerman, 2012, Lung cancer management.